Wednesday, December 05, 2018 12:23:24 AM
If we had 17 years of patent protection - take all the friggin time we want
We don't have that
We have limited "extreme" value to BP before generics come to life
Vascepa will be on life support after that.
Let me give everyone a few examples of real world events that we are up against:
I started on Vascepa after threatening my cardiologist 2 years ago - only knew about drug because i invested in it
I did no dieting or exercise at all - my TG went from 160 to 95 on 1 pill per day
My Glucose went from 160 to 95 - first time in 25 years i was not pre-diabetic - my cardiologist put me on 2 pills of Vascepa/day
after reduce-it, i asked for 4 pills per day - got it
In april of this year, i went on massive diet and running campaign - lost 60 pounds - my TG are now 44 and glucose is the same
So i went to my Cardiologist last week - he saw my results and we talked about reduce-it and he said "why don't we take you off Vascepa and look at bloodwork in 6 months. since obviously results of new bloodwork was results of diet and exercise" I said no way. He is one of top rated Dr in DE
My brother went to his doctor - got script and insurance company said he needs to try Lovaza first unless Doctor writes letter - doctor said nope
another brother, who is a doctor, needed to bring reduce-it report to his doctor to get script
My other brother who has 3 stents - his doctor wants to wait for NEJM to be published
All true stories - this is not a DS that you can just get at CVS - this needs a doctor's script
Also people who post on this board who say that they are massive longs in this stock who say they take DS Omegas instead of Vascepa - no matter what the cost - are MORONS - I repeat MORONS
Read the last 3 trials reported - You are taking CRAP - no one monitors what is in those pills - i was on DS for 20 years - they do absolutely nothing - and i would pay anything for Vascepa - no matter what
So those who say they don't take Vascepa and are longs - I say BS - stop posting - because you are all full of it. Unless Vascepa is not in your Country like HDG
HDG posted we need 154000 scripts to get to $1 billion sales - yeah- we (board members here) are going to drive sales to these numbers - PEOPLE WAKE UP TO FACTS
This drug needs to be in hands of every statin user in world and then some - and i mean right now - I am sorry but only a BP has the power and might to do this.
AMRN should gets best deal ASAP for everyone in world
If not we should sell all shares now - because by June this will be under 10 - and buy back later - because sales will not get up to where want until 2021
IMHO, that would be a shame that this drugs is not helping max amount of people as fast as possible
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM